JOB 2014-12-29 Employer Roivant Sciences, Inc. Principal Investigator Lawrence Friedhoff Contact firstname.lastname@example.org Description Roivant recently acquired the rights to a Phase 3 drug for the treatment of Alzheimer’s disease. The drug has demonstrated ...
CONFERENCE 2015-04-27 00:00:00-2015-04-29 00:00:00 Hyatt Regency Boston Hotel, Boston, Massachusetts, U.S.A. 27 – 29 April 2015 The summit includes two parallel conferences thatinclude joint sessions. GTCbio's Stem Cell Summit 2015 provides cutting-edge information on developments in all ...
RESEARCH NEWS 2014-12-29 Research News Aβ oligomers are widely seen as the cause of synaptic damage and cognitive decline in Alzheimer’s disease. Researchers want to be able to detect these peptides in vivo to better diagnose and track the progression of AD. In an effort to ...
PAPER Jitlal M, Khan I, Lee SM, Hackshaw A
Stopping clinical trials early for futility: retrospective analysis of several randomised clinical studies.Br J Cancer. 2012 Sep 4;107(6):910-7. Epub 2012 Aug 9 PubMed: 22878376
CEA CNRSFontenay-aux-roses, France
H. Lundbeck A/SValby, Denmark
Other Research Models Hi, Anyone can let me know that for "Transcriptomic analysis of the Type 2 Diabetes induced Alzheimer disease in mice model" which mice model I should choose. Though I come to know about TAPP transgenic mice model (Ref: 1. ...
King Abdulaziz UniversityJeddah, Saudi Arabia
Inverness, United States
PAPER Yang XL25512555
PAPER Ivanov P, Emara MM, Villen J, Gygi SP, Anderson P21855800
No filters selected